Improve Reproducibility, Manage Costs, & Accelerate Timelines Through Selecting & Combining Tumour Models to Deliver Novel Targets, Faster Insights & Stronger Clinical Translation
The 15th Tumour Models Summit London is Europe's longest-standing and most comprehensive meeting dedicated to advancing preclinical and translational tumour modelling.
As oncology pipelines become increasingly dependent on immunotherapies, cell therapies, ADCs, radioligand therapies, and precision medicines, development teams face growing pressure to improve translational confidence, identify predictive models, and generate decision-grade evidence earlier in development.
Join leaders from Roche, AstraZeneca, Johnson & Johnson, Eli Lilly, Immunocore, Merck, Molecular Partners, ImmunoKey, and innovative oncology biotechs to explore how human-relevant models, NAMs, AI-enabled approaches, patient-derived systems, biomarkers, tumour microenvironment models, and integrated development strategies can improve candidate selection, predict clinical outcomes, and reduce late-stage attrition.
Whether your focus is model validation, safety prediction, tumour microenvironment biology, translational biomarkers, AI-driven prediction, or regulatory strategy, this is the industry's definitive forum for improving oncology model translatability.
This meeting brings together the drug developers, translational scientists and clinicians who share the challenge of turning preclinical promise into genuine clinical benefit in glioblastoma. For us, the value lies in comparing how others interpret and de-risk their tumour-model data, pressure-testing our own translational assumptions, and building the cross-company dialogue that ultimately helps more candidates reach the patients who urgently need better options.
Adam Robertson, Chief Scientific Officer, Hemispheria
It will be excellent to engage with service providers who can help us with our development plans.
John Bridgeman, Chief Scientific Officer – ImmunoKey
A great meeting that allowed for meaningful connections with everyone. Well-designed and engaging. Definitely will attend again!
Boguslaw Nocek, Senior Director, Eli Lilly
Explore the 2026 Event Guide
- Free* to attend for biotech & pharma
- Discover how Roche, AstraZeneca & J&J are improving translational confidence
- Explore how AI and computational modelling are transforming oncology decision-making
- Benchmark emerging human-relevant models, NAMs & tumour microenvironment platforms
- Learn practical strategies to improve model validation and predictive power
- Preview 20+ industry-led case studies, evidence presentations & insight exchanges
Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Discover how leading oncology teams are building more predictive, translationally relevant tumour models.
Partner With Us
Meet the scientists and decision-makers actively evaluating new model systems, biomarkers, NAMs and CRO partners.
Join Industry Experts
Benchmark strategies with biology, pharmacology, translational and safety leaders from across pharma and biotech.